The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) is a huge mover today! About 64,674 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 7.68% since March 7, 2016 and is downtrending. It has underperformed by 15.27% the S&P500.
The move comes after 5 months positive chart setup for the $526.76M company. It was reported on Oct, 10 by Barchart.com. We have $31.06 PT which if reached, will make NASDAQ:ATRA worth $352.93M more.
Analysts await Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings on November, 3. They expect $-0.69 earnings per share, down 60.47% or $0.26 from last year’s $-0.43 per share. After $-0.66 actual earnings per share reported by Atara Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.
Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage
Out of 5 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 3 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 60% are positive. Atara Biotherapeutics has been the topic of 12 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Citigroup downgraded the shares of ATRA in a report on Tuesday, December 15 to “Sell” rating. The company was maintained on Tuesday, December 15 by JMP Securities. The stock has “Outperform” rating given by William Blair on Friday, October 9. Goldman Sachs downgraded the shares of ATRA in a report on Thursday, September 15 to “Sell” rating. JMP Securities initiated Atara Biotherapeutics Inc (NASDAQ:ATRA) on Friday, September 25 with “Mkt Perform” rating. The stock has “Neutral” rating given by Goldman Sachs on Wednesday, November 18. The stock has “Sell” rating given by Citigroup on Monday, August 22. Canaccord Genuity initiated the stock with “Buy” rating in Wednesday, September 9 report. As per Friday, August 19, the company rating was maintained by Citigroup. JMP Securities maintained Atara Biotherapeutics Inc (NASDAQ:ATRA) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $34 price target.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
Insitutional Activity: The institutional sentiment increased to 3.36 in 2016 Q2. Its up 2.20, from 1.16 in 2016Q1. The ratio is positive, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Baupost Grp Inc Llc Ma accumulated 5.36M shares or 1.64% of the stock. Proshare Advsr Ltd Llc has invested 0.01% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Vident Advisory has 0.1% invested in the company for 32,879 shares. Metropolitan Life Insur Ny last reported 0% of its portfolio in the stock. Blackrock Fund Advisors has 913,922 shares for 0% of their US portfolio. Blackrock Gru Ltd accumulated 0% or 5,334 shares. Wells Fargo Mn last reported 36,842 shares in the company. Voya Investment Management holds 10,162 shares or 0% of its portfolio. Bnp Paribas Arbitrage last reported 937 shares in the company. Fmr Ltd Liability Corporation accumulated 3.13 million shares or 0.01% of the stock. National Bank Of New York Mellon accumulated 99,629 shares or 0% of the stock. Geode Management Lc last reported 137,725 shares in the company. Teachers Advsrs has invested 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). The Germany-based Dekabank Deutsche Girozentrale has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). 12 West Cap Management Ltd Partnership last reported 398,700 shares in the company.
Insider Transactions: Since April 11, 2016, the stock had 0 insider buys, and 15 selling transactions for $1.86 million net activity. Soffer Gad sold $120,040 worth of stock. The insider Ciechanover Isaac E. sold $214,368. Another trade for 5,395 shares valued at $85,079 was sold by MCGRATH JOHN. Clark Mitchall G. sold $62,918 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Monday, May 16. Shares for $30,041 were sold by Haqq Christopher. Shares for $18,897 were sold by Gallagher Carol Giltner on Monday, May 16.
More important recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on October 17, 2014, also Fool.com published article titled: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today”, Quotes.Wsj.com published: “News Atara Biotherapeutics Inc.ATRA” on July 19, 2014. More interesting news about Atara Biotherapeutics Inc (NASDAQ:ATRA) was released by: Benzinga.com and their article: “Atara Biotherapeutics Has 25% Downside” with publication date: September 15, 2016.
ATRA Company Profile
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.